CorMedix

Acquisition And Pipeline Expansion Will Unlock Healthcare Potential

AnalystConsensusTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

30 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$20.00

35.4% undervalued

15 Aug

US$12.93

150.6%

28.4%

Author's Valuation

US$20.0

35.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$20.0

35.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

20.06%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$384.31m

Earnings '28

10.39x

PE Ratio '28

US$3.99b

Market Cap '28

US$3.99b

Market Cap '28

164.00m

No. shares '28

US$24.35

Share Price '28

US$24.35 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$20.00

Fair Value '25